Pharmacologic activation of expression of immunodominant viral antigens: a new strategy for the treatment of Epstein-Barr-virus-associated malignancies.
Robertson
K D
KD
Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Barletta
J
J
Samid
D
D
Ambinder
R F
RF
D000328:Adult; D000956:Antigens, Viral / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D001483:Base Sequence; D002051:Burkitt Lymphoma / Q000235:genetics / Q000473:pathology / Q000821:virology; D004273:DNA, Neoplasm / Q000235:genetics; D004279:DNA, Viral / Q000235:genetics; D004268:DNA-Binding Proteins / Q000096:biosynthesis* / Q000235:genetics; D000077209:Decitabine; D019309:Epstein-Barr Virus Nuclear Antigens; D015967:Gene Expression Regulation, Viral / Q000187:drug effects*; D006566:Herpesviridae Infections / Q000188:drug therapy*; D004854:Herpesvirus 4, Human / Q000187:drug effects* / Q000235:genetics / Q000276:immunology; D006801:Humans; D016056:Immunodominant Epitopes / Q000096:biosynthesis* / Q000235:genetics; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000821:virology; D008745:Methylation; D008969:Molecular Sequence Data; D016133:Polymerase Chain Reaction; D014407:Tumor Cells, Cultured; D014412:Tumor Virus Infections / Q000188:drug therapy*; D014763:Viral Matrix Proteins / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D014775:Virus Activation / Q000187:drug effects*
D000956:Antigens, Viral; D004273:DNA, Neoplasm; D004279:DNA, Viral; D004268:DNA-Binding Proteins; C037662:EBV-associated membrane antigen, Epstein-Barr virus; D019309:Epstein-Barr Virus Nuclear Antigens; D016056:Immunodominant Epitopes; D014763:Viral Matrix Proteins; D000077209:Decitabine; D001374:Azacitidine